Overview

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Topotecan